ArticleRegenerative therapy2025
Hydrogel microcapsulation technology reduces the DMSO concentration required for stem cell cryopreservation.
Article in Regenerative therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multifunctional Agarose-Based Biomaterials: From Tissue Engineering and Immunomodulation to Advanced Diagnostics and Translational Applications.Gels (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Stem cell therapy is increasingly advancing towards clinical applications, with cryopreservation playing a critical role in cell transplantation. Previous studies have demonstrated that hydrogel microcapsules can enhance cell survival during cryopreservation. However, most research has focused on rapid freezing techniques or cryopreservation with high-concentration dimethyl sulfoxide (DMSO). This study aims to investigate the effects of hydrogel microcapsules on the viability, phenotype, and functionality of mesenchymal stem cells (MSCs) following cryopreservation with low-concentration DMSO. The objective is to develop a safer cryopreservation strategy for clinical stem cell applications. Methods: In this study, We utilized five concentrations of DMSO (0 %, 1.0 %, 2.5 %, 5.0 %, 10.0 %(v/v)) to cryopreserve fabricated MSCs-laden microcapsules. We analyzed the effects of varying DMSO concentrations on the viability of microencapsulated MSCs, and the impact of hydrogel microcapsules on MSCs quality after cryopreservation with 2.5 % DMSO was investigated, including cell viability, morphology, phenotype, the expression of stemness-related genes and multidirectional differentiation potential. Results: The results showed that when the DMSO concentration was reduced to 2.5 %, cell viability reached the minimum requirement (70 %) for clinical treatment, and it was demonstrated that, under low-concentration DMSO cryopreservation, the microencapsulation technique did not alter the stem cell phenotype and differentiation potential, and improved stem cell viability. Conclusions: Hydrogel microencapsulation technology can reduce the concentration of DMSO required in stem cell cryopreservation and mitigate cryoinjury to cells. The cryopreservation of three dimensional (3D) cell constructs based on cell-biomaterials provides a highly promising new strategy for efficient stem cell storage and clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.